Project Grant P01HL183482
Award Date 9/5/25
Completion Date 6/30/30
Dollars Obligated $3.5M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92037, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $3,693,667 to the University of Southern California (USC) to develop an HIV cure through in vivo cell engineering. The key focus areas include: New gene therapy vector formulations and gene editing tools to precisely modify hematopoietic stem cells, T cells, and B cells. Surface-accessible bone marrow cryogel ports to facilitate in vivo cell engineering and direct...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $249,000 to support research focused on developing gene-edited primary human cells that can enhance HIV-1 resistance. The research aims to achieve greater than 90% deletion of the CCR5 co-receptor and up to 50% allelic knock-in of inhibitory peptides targeting viral fusion and uncoating, resulting in significant inhibition of both CCR5- and CXCR4-tropic HIV...
- The University of Southern California received a $162,486 Project Grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to engineer B cells for enhanced HIV control. The 4.5-year project, which began on February 1, 2025, aims to develop an approach to provide necessary T cell help and produce broadly neutralizing antibody-engineered B cells that would be functional in people living with HIV. Key objectives include...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $910,905 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute in La Jolla, CA. The grant, awarded on July 1, 2025, supports the development of an HIV vaccine using a lipid nanodisc platform to incorporate the envelope (Env) glycoprotein of HIV. The project aims to enable scalable and reproducible in vitro characterization and optimization of engineered...
- This $118,488 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) on January 20, 2025, supports research to develop HIV-resistant hematopoietic stem cells through targeted base editing. The project aims to identify genetic mutations in the CCR5 and CXCR4 co-receptors that can prevent HIV entry into CD4 cells while maintaining the central functions of these proteins in hematopoiesis. The research involves...
- The Scripps Research Institute received a $102,893 Project Grant award from the Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute on February 17, 2021 to develop potent and specific small molecule stabilizers of amyloidogenic antibody light chains. The grant supports research under the Cardiovascular Diseases Research program (CFDA #93.837), which aims to foster basic, translational, clinical and population sciences research on heart...
- The National Heart Lung and Blood Institute (NHLBI) awarded a $3,264,423 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) to study the mechanisms underlying the increased risk of sudden cardiac death in people with HIV. The research aims to characterize the myocardial tissue effects of treated HIV, including immune activation, cardiac ion channel dysregulation, and region-specific arrhythmic...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,379,954 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The grant, awarded on August 21, 2025, supports research to engineer durable immunity by optimizing HIV vaccine parameters to drive long-lived plasma cell development. The project aims to systematically study the effects of immunogen affinity, valency, adjuvants, vaccine platforms, and...
- The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $852,121.24 to The Scripps Research Institute-Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of July 22, 2021 through October 31, 2021. The project aims to identify host factors that regulate HIV latency and reactivation in order to develop strategies for durable HIV silencing. The grantee will define the roles of three identified host factors, P32,...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Gigamune, Inc. to develop an in vivo gene therapy for sickle cell disease. The project aims to test a novel lentiviral vector technology for efficiently editing hematopoietic stem cells to knockout the BCL11A enhancer, a key genetic target for sickle cell treatment. Through in vitro assays, the Phase I effort will...